Evidence map›Paper›PMID 32207816›Full record

ArticleJAMA2020

Prevalence and Outcomes of Infection Among Patients in Intensive Care Units in 2017.

Jean-Louis Vincent, Yasser Sakr, Mervyn Singer, Ignacio Martin-Loeches, Flavia R Machado, John C Marshall, Simon Finfer, Paolo Pelosi, Luca Brazzi, Dita Aditianingsih and 14 more

2 registry-linked trialsOpen access · bronzeAbstract read
In one paragraph

Article in JAMA, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 488 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
488citing papers in PubMed, 6 pooled it
58.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06246994 unknown statusnot on this mapstarted 2024, after this paper: background citation

Predictors of Mortality Among Ventilator Associated Pneumonia Patients

TypeobservationalSponsorAssiut UniversityRan2024 to 2025Enrolled140ConditionsPneumonia
NCT07211620 narecruitingnot on this mapstarted 2025, after this paper: background citation

KInetics of Procalcitonin to Reduce Unnecessary aNtibiotic Use (KIPRUN) - Protocol for a Multi-center, Randomized, Superiority Trial to Compare the Efficacy and Safety of Procalcitonin Kinetics-guided and Absolute Procalcitonin Value-guided Antibiotic Initiation in Reducing Unnecessary Antibiotic Therapy in Critically Ill Patients

TypeinterventionalSponsorSemmelweis UniversityRan2025 to 2027Enrolled250ConditionsInfection, SepsisArmsKinetics, Absolute
3 · Its place in the literature

Who cites it

488 citing papers in PubMed, 6 syntheses or guidelines pooled it, 982 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. [S3 guideline on sepsis-prevention, diagnosis, therapy, and follow-up care-update 2025].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2025
    Guideline
  4. Pooled it
  5. Guideline
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Redox protection by bacterial glutathione peroxidase drives virulence inRedox report : communications in free radical research · 2026
    Article
  12. Review
  13. Clinical metagenomics: a call to action.Intensive care medicine · 2026
    Article
  14. Review
  15. Review
  16. Article
  17. Observational
  18. Article
  19. Article
  20. Hour-1 Sepsis Bundle: Updated Evidence.Journal of clinical medicine · 2026
    Review

428 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors at 20 institutions in 18 countries.

Jean-Louis VincentDepartment of Intensive Care, Erasme University Hospital, Université Libre de Bruxelles, Brussels, Belgium.
Yasser SakrDepartment of Anesthesiology and Intensive Care, Uniklinikum Jena, Jena, Germany.
Mervyn SingerBloomsbury Institute of Intensive Care Medicine, University College London, London, England.
Ignacio Martin-LoechesDepartment of Intensive Care Medicine, Multidisciplinary Intensive Care Research Organization, St James's Hospital, Dublin, Ireland.
Flavia R MachadoIntensive Care Department, Universidade Federal de São Paulo, São Paulo, Brazil.
John C MarshallLi Ka Shing Knowledge Institute, St Michael's Hospital, Toronto, Ontario, Canada.
Simon FinferGeorge Institute for Global Health, University of New South Wales, Sydney, Australia.
Paolo PelosiDepartment of Surgical Sciences and Integrated Diagnostics, University of Genoa, Genoa, Italy.
Luca BrazziDepartment of Surgical Science, University of Turin, University Hospital Città della Salute e della Scienza, Turin, Italy.
Dita AditianingsihDepartment of Anesthesia and Intensive Care, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta.
Jean-François TimsitMedical and Infectious Diseases ICU, AP-HP, Bichat-Claude Bernard University Hospital, Paris, France.
Bin DuMedical ICU, Peking Union Medical College Hospital, Beijing, China.
Xavier WitteboleCritical Care Department, Cliniques Universitaires St Luc, UCL, Brussels, Belgium.
Jan MácaDepartment of Anesthesiology and Intensive Care Medicine, University Hospital of Ostrava, Ostrava, Czech Republic.
Santhana KannanDepartment of Anaesthesia and Critical Care, SWBH Trust, Birmingham, England.
Luis A Gorordo-DelsolUnidad de Cuidados Intensivos Adultos, Hospital Juárez de México, Mexico City.
Jan J De WaeleDepartment of Critical Care Medicine, Ghent University Hospital, Ghent, Belgium.
Yatin MehtaMedanta Institute of Critical Care and Anesthesiology, Medanta The Medicity, Gurugram, India.
Marc J M BontenDepartment of Medical Microbiology, University Medical Center, Utrecht University, Utrecht, the Netherlands.
Ashish K KhannaDepartment of Anesthesiology, Section on Critical Care Medicine, Wake Forest University School of Medicine, Wake Forest Baptist Medical Center, Winston-Salem, North Carolina.
Marin KollefDivision of Pulmonary and Critical Care Medicine, School of Medicine, Washington University in St Louis, St Louis, Missouri.
Mariesa HumanLevel l Trauma Centre, Netcare Union/Clinton Hospitals, Alberton, South Africa.
Derek C AngusDepartment of Critical Care Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.
EPIC III Investigators
Atrium Health Wake Forest Baptist · USBury College · GBCentro de Investigación Biomédica en Red de Enfermedades Respiratorias · ESChinese Academy of Medical Sciences & Peking Union Medical College · CNCliniques Universitaires Saint-Luc · BEGhent University Hospital · BEHospital Juárez de México · MXJena University Hospital · DEMedanta The Medicity · INNetcare Unitas Hospital · ZAOspedale Policlinico San Martino · ITSt. Michael's Hospital · CAUniversidade Federal de São Paulo · BRUniversité Claude Bernard Lyon 1 · FRUniversité Libre de Bruxelles · BEUniversity Hospital Ostrava · CZUniversity of Indonesia · IDUniversity of Pittsburgh · USUniversity of Turin · ITUNSW Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

importanceInfection is frequent among patients in the intensive care unit (ICU). Contemporary information about the types of infections, causative pathogens, and outcomes can aid the development of policies for prevention, diagnosis, treatment, and resource allocation and may assist in the design of interventional studies.

objectiveTo provide information about the prevalence and outcomes of infection and the available resources in ICUs worldwide. DESIGN, SETTING, AND

participantsObservational 24-hour point prevalence study with longitudinal follow-up at 1150 centers in 88 countries. All adult patients (aged ≥18 years) treated at a participating ICU during a 24-hour period commencing at 08:00 on September 13, 2017, were included. The final follow-up date was November 13, 2017. EXPOSURES: Infection diagnosis and receipt of antibiotics. MAIN OUTCOMES AND MEASURES: Prevalence of infection and antibiotic exposure (cross-sectional design) and all-cause in-hospital mortality (longitudinal design).

resultsAmong 15 202 included patients (mean age, 61.1 years [SD, 17.3 years]; 9181 were men [60.4%]), infection data were available for 15 165 (99.8%); 8135 (54%) had suspected or proven infection, including 1760 (22%) with ICU-acquired infection. A total of 10 640 patients (70%) received at least 1 antibiotic. The proportion of patients with suspected or proven infection ranged from 43% (141/328) in Australasia to 60% (1892/3150) in Asia and the Middle East. Among the 8135 patients with suspected or proven infection, 5259 (65%) had at least 1 positive microbiological culture; gram-negative microorganisms were identified in 67% of these patients (n = 3540), gram-positive microorganisms in 37% (n = 1946), and fungal microorganisms in 16% (n = 864). The in-hospital mortality rate was 30% (2404/7936) in patients with suspected or proven infection. In a multilevel analysis, ICU-acquired infection was independently associated with higher risk of mortality compared with community-acquired infection (odds ratio [OR], 1.32 [95% CI, 1.10-1.60]; P = .003). Among antibiotic-resistant microorganisms, infection with vancomycin-resistant Enterococcus (OR, 2.41 [95% CI, 1.43-4.06]; P = .001), Klebsiella resistant to β-lactam antibiotics, including third-generation cephalosporins and carbapenems (OR, 1.29 [95% CI, 1.02-1.63]; P = .03), or carbapenem-resistant Acinetobacter species (OR, 1.40 [95% CI, 1.08-1.81]; P = .01) was independently associated with a higher risk of death vs infection with another microorganism. CONCLUSIONS AND RELEVANCE: In a worldwide sample of patients admitted to ICUs in September 2017, the prevalence of suspected or proven infection was high, with a substantial risk of in-hospital mortality.

Indexed as

Cross InfectionAdultAnti-Bacterial AgentsAsiaCross-Sectional StudiesHumansIntensive Care UnitsMaleMiddle AgedMiddle EastPrevalenceAnti-Bacterial Agents

Identifiers

PMID32207816
PMCPMC7093816
OpenAlexW3012868903

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.